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Purpose: Women undergoing radical cystectomy (RC) and urinary diversion for bladder cancer experience
substantial limitations in health-related quality of life (HRQOL). However, the level of discomfort caused by different
urinary diversion has been never evaluated in long term survivors. The aim of this multicenter study is to evaluate
differences in HRQOL among recurrence-free women undergoing cutaneous ureterostomy (CUS), Bricker's ileal
conduit (BK-IC) and Orthotopic neobladder VIP (ONB-VIP) in disease-free females treated with radical cystectomy
(RC), with long-term follow up (mean 60.1 months; range 36-122 months).
Materials and methods: All consecutively treated female patients from two urological institutions who underwent
RC and urinary diversion from January 2000 to December 2008, with no evidence of tumor recurrence at a
minimum follow up of 36 months, were included. Patients received the European Organisation for Research and
Treatment of Cancer (EORTC) generic (QLQ-C30) and bladder cancer-specific instruments (QLQ-BLM30) and the
Functional Assessment of Cancer Therapy for Bladder Cancer (FACT-BL). Clinical data and questionnaire results were
analyzed in order to evaluate the HRQOL differences among diversion groups.
Results: We identified 37 females (median age: 68, range 45–82 years), including 12 status-post CUS, 16 who
underwent BK-IC, and 9 who underwent ONB-VIP. Most were healthy (24/37 with no comorbidities, 4/37 Charlson
1-2, 9/37 Charlson 3 or greater – we didn’t considered bladder cancer in Charlson evaluation because bladder
cancer was the main inclusion criteria). Women undergoing CUS endorsed worse FACT-BL scores compared with
BK-IC and ONB-VIP patients, worse HRQOL regarding physical and emotional well-being (p=0.008 and p=0.02,
respectively), and a trend toward worse EORTC QLQ-C30 scores for appetite loss and fatigue (p=0.05 for both).
Conclusions: In our study long-term disease-free females treated with CUS endorsed worse HRQOL compared with
women who underwent BK-IC or ONB-VIP, mostly due to worse physical and emotional perception of their body
image.
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Bladder cancer (BC) ranks ninth in worldwide cancer
incidence. It is the 7th most common cancer in men
and the 17th most common cancer in women with
more than 330,000 new cases each year and more than
130,000 deaths per year [1]. According to the European
Association of Urology (EAU) and National Compre-
hensive Cancer Network guidelines (NCCN), radical
cystectomy (RC) is the standard treatment for localized
muscle-invasive bladder cancer and high-risk non-muscle-
invasive cancers resistant to endovesical chemothera-
py [2].
In contemporary series, patients may achieve excellent
long-term functional and oncologic outcomes when
treated at high-volume institutions by experienced sur-
geons. Beyond the primary aim of disease control, re-
moval of the bladder requires reconstruction of a lower
urinary tract. Surgeons can reconstruct complex urinary
diversions that also safeguard patients’ health-related
quality of life (HRQOL) [3], but this is a highly morbid
surgical procedure associated with significant changes in
urinary and sexual function, strained relationships, and
psychosocial stress [4]. For this reason, in the last years,
the evaluation of HRQOL after such an impacting pro-
cedure has garnered increasing interest [5].
Several studies have attempted to evaluate HRQOL
following RC and focused on the effects of various types
of lower urinary tract reconstruction [6,7]. Hobisch et al.
found that HRQOL was preserved to a higher deg-
ree with a continent orthotopic neobladder (ONB-VIP:
where last tract of ileal bowel is reconfigured into a
sphere and sewn to the urethral stump to facilitate
voiding per urethra) compared with an incontinent di-
version like cutaneous ureterostomy (CUS: where ure-
ters are connected to the surface of the abdomen with
the formation of an opening stoma) and ileal conduit
urinary diversion (BK-IC: where the urine is diverted to
a bag on the skin, made by short tract of small bowel)
[8]. Similarly, Heningssohn et al., compared a cohort of
patients that underwent RC and orthotopic bladder sub-
stitution with a matched non-operative control group
and demonstrated preserved global quality of life [9].
Yet, other studies comparing different types of urinary
diversion were unable to confirm superiority of one type
of reconstruction with regard to HRQOL [10-12]. Re-
cently, Hedgepeth, et al., showed no difference in body
image scores between IC and ONB patients after surgery
[13]. However, many of these reports have no long-term
follow up, and often include very few recurrence-free fe-
male patients.
The aim of this study is to evaluate differences in
HRQOL between different forms of urinary diversion in
a consecutive series of female who had RC for muscle-
invasive bladder cancer. We concentrated on long term(3years or more) recurrence-free females in order to as-
sess HRQOL in a cohort that would not be biased by
bladder cancer treatments.
Materials and methods
Study design
In order to evaluate the differences in terms of HRQOL
among women treated with CUS, or BK-IC or ONB-VIP
after RC for clinically localized bladder cancer, all con-
secutively female patients treated in two urological insti-
tutions from January 2000 to December 2008 without
any evidence of tumor recurrence after at least 36 months
from surgery were considered for this study. We enrolled
disease-free patients in order to exclude bother related to
adjuvant and salvage therapies and avert the social/emo-
tional implication of disease progression. Another reason
to enroll patients after at least 36 months after surgery
was to avoid the biases of peri-operative care (more com-
plex urinary diversions require more intensive nursing
care in the postoperative recovery period).
All patients were retrospectively assessed with the
following self-administered questionnaires (they had
help to filling the questionnaire in if it was needed): the
European Organization for Research and Treatment of
Cancer (EORTC) generic (QLQ-C30) and bladder cancer-
specific surveys (QLQ-BLM30) and the Functional
Assessment of Cancer Therapy for Bladder Cancer
(FACT-BL). For analysis, patients were stratified according
to urinary diversion type.
Subsequently the responses were entered into a data-
base. Data from the questionnaires were analyzed in
order to test differences among the groups. Informed
consent was obtained from all patients. The study was
conducted in accordance with the principles of research
involving human subjects as expressed in the Declar-
ation of Helsinki and with Good Clinical Practice.
Inclusion and exclusion criteria
Included patients were at least 18 years of age, who
underwent RC and urinary diversion for clinically local-
ized bladder cancer in accordance with EAU criteria
[14]. Only disease free females at least 36 months after RC
were included in this study. All enrolled patients were able
to ply the study design, including to self compile the se-
lected questionnaires. We excluded patients with major
concomitant medical or psychological diseases, including
those with remarkable bowel disease and those with previ-
ous lower tract surgery, with the exception of staging
TURBT. Likewise, patients previously treated with neoad-
juvant chemotherapy or radiation therapy were excluded.
Surgical techniques and surveillance
Patients were followed according to the surveillance
schedules suggested in EAU guidelines [14]. RC with
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by Skinner, et al [15]. ONB-VIP was performed in pa-
tients without locally advanced disease (including absence
of hydroureteronephrosis) or bladder neck involvement,
normal renal and bowel function, and functional capability
to manage urinary diversion. For those women who did
not meet criteria for ONB, we performed a non-ortho-
topic urinary diversion. All procedures were performed by
two dedicated surgeons.
We classified perioperative complications according to
the Clavien–Dindo classification [16]. For risk adjust-
ment, we calculated each patient’s Charlson Comorbidity
Index [17]. Follow-up after urinary diversion was sched-
uled every 3 months during the first 2 years and subse-
quently every 6 months for 5 years or more. Follow up
included general physical examination, routine serum
chemistries, urinary cytology, total abdominal US, chest
x-ray, CT urography, and cystoscopy (only in very se-
lected cases).
HRQOL measurement and questionnaire descriptions
We used the general and bladder cancer-specific HRQOL
questionnaires EORTC QLQ-C30 [18], EORTC QLQ-
BLM30 [19] and FACT-BL [20]. All questionnaires were
self-administered during a scheduled follow-up visit.
EORTC QLQ-C30
We used the Italian version of the EORTC QLQ-C30. In
brief, the EORTC QLQ-C30 is a 30-item questionnaire
composed of multi-item scales and single items that re-
flect the multidimensionality of the quality-of-life con-
struct [18]. It incorporates five functional scales (physical,
role, cognitive, emotional, and social), three symptom
scales (fatigue, pain, and nausea/vomiting), and a global
health and quality-of-life scale. The remaining single items
assess additional symptoms commonly reported by cancer
patients (dyspnea, loss of appetite, sleep disturbance, con-
stipation, and diarrhea), as well as the perceived financial
impact of cancer and its treatment [18]. The majority of
questions were assigned a score from one to four (1=not
at all, 4= very much) [18]. Questions 29 and 30 were
assigned a score from 1 to 7. All scores were linearly
transformed to a 0-100 scale. Lower score matches to
higher HRQOL
EORTC QLQ -BLM30
We used the validated Italian version of QLQ-BLM30
from EORTC to assess bladder cancer-specific HRQOL
[19]. All questions are specific to patients treated for
muscle-invasive bladder cancer. The EORTC QLQ-
BLM30 was developed to evaluate the HRQOL detriments
associated with having a urostomy and measures the ef-
fects of the urostomy appliance on patients’ HRQOL fol-
lowing urinary diversion [19]. Patients with continentcutaneous pouches can answer questions concerning their
ability to perform catheterization. Due to the fact that
cystectomy and urinary diversion involves major physical
changes, the instrument is also designed to assess any
changes in the patient’s body image. Moreover, it evaluates
the physical changes that affect the patient’s sexual life
and the patient’s mood [18]. Finally, the bowel aspect was
evaluated in relation to presence of intestinal reconfigur-
ation. Each question was assigned a score from one to
four (1=not at all, 4= very much) [19]. All scores were
linearly transformed to a 0-100 scale. Lower score mat-
ches to higher HRQOL
FACT (BL-VCI)
The FACT-BL similarly evaluated patients’ bladder can-
cer-specific HRQOL. We used the validated Italian
version of FACT-BL [20]. FACT-BL is useful for compar-
isons of the HRQOL of patients with various diversions
including an ileal conduit, a continent cutaneous reser-
voir, or an orthotopic neobladder. The scores were cal-
culated from the FACT-BL questionnaire and subsetted
into the domains of: physical well-being (PWB), social/
family well-being (SWB), emotional well-being (EWB),
functional well-being (FWB), total FACT-G score (which
is incorporated into the FACT-BL), overall bladder
cancer-specific subscale, and total FACT-BL score
(FACT-G + bladder cancer subscale) [20]. The survey
is composed of 39 questions. Each question was as-
signed a score from one to four (1=not at all, 4= very
much) [20]. A total of 17 additional questions were
added to the FACT-G to create the Vanderbilt Cystec-
tomy Index (FACT-VCI) [20]. Lower score matches to
higher HRQOL.
Statistical analysis
As null hypothesis we assumed that there was no dif-
ference among the urinary diversion groups in terms
of HRQOL. Continuous, normally distributed variables
were reported as the mean value with standard deviation
(SD). Summary scores and responses to individual items
are presented using descriptive statistics.
All data were stratified according to urinary diversion
with univariate ANOVA analyses (all diversions) and
with unpaired sample T tests. Statistical significance was
achieved if p was <0.05. All reported p-values were two-
sides. All data were recorded, collected and analyzed by
using Statistical Package for the Social Sciences 16.0 for
Microsoft (SPSS, Inc., Chicago, Illinois, USA).
Results
We enrolled 41 female patients who had RC for muscle
invasive bladder cancer without any evidence of tumor
recurrence after at least 36 months from surgery. 4 pa-
tients were excluded: 1 had serious inflammatory bowel
Table 1 Clinical and pathological characteristics of our
study patients, stratified according to different urinary
diversion
CUS Bricker VIP
12 16 9
Age at follow up,
mean ± SD
75.3 ± 10.8 74.4 ± 8.8 71.8 ± 7.0
Pathological stage
classification
pT1 /Tis 4 (%) 6 (%) 0 (%)
pT2 3 (%) 7 (%) 4 (%)
pT3 5 (%) 3 (%) 5 (%)
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gery. Overall, a total of 37 females patients were in-
cluded in the study. Mean age at surgery was 67.3 ± 8.7
years; mean age at follow-up was 73.1 ± 8.7 years. Clini-
cal and pathological characteristic of the patients at sur-
gery, stratified by urinary diversion type, are described in
Table 1.
Twelve women were treated with CUS, 16 with BK-IC
and 9 with ONB-VIP. Comorbidity counts were 0 in 24
patients, 1-2 in 4 patients, and 3 in 9 patients. All groups
were similar according to clinical, pathological and peri-
operative characteristics at the time of RC. All pa-
tients were disease-free at most recent follow-up (mean
60.1 months; range 36-122 months).
Functional outcomes
All included patients completed all the questionnaires.
More remarkable subscores of all questionnaires are
reported in Table 2. The EORTC QLQ-C30 identified a
trend toward worse HRQOL for “appetite loss” and “fa-
tigue” among CUS patients compared with BK-IC or
ONB-VIP (1.50 vs 1.12 and 1.96 vs 1.51, respectively,Table 2 Average scores of any considerable specific subscales
urinary diversion
Questionnaire Subscale CUS av
EORTC QLQ C 30 Total score 28.1 ±
Physical function 1.8
Diarrhea 2.5
Appetite loss 1.5
Fatigue 2.0
EORTC QLQ BLM 30 Total score 7.3 ± 2
Body image 2.3
Sexual functioning 0.6
FACT-BL Total score 7.8 ± 2
Social well being 1.9
Functional well being 1.8
Physical well being 1.3
Emotional well being 1.7
In bold significant p value (*unpaired T test: CUS vs BK+VIP).p=0.05 for both analyses). The FACT-BL questionnaire
demonstrated significantly worse “physical well-being”
(Additional file 1: Figure S1) and “emotional well-being”
(Additional file 2: Figure S2) for CUS compared with
BK-IC or ONB-VIP (p=0.008 and p=0.02, respectively).
No other differences in questionnaire results among the
three urinary diversions groups was reported. In relation
to sexual function, no difference among the diversion
groups was recognized.
Discussion
In the last two decades, there has been a growing recog-
nition of the importance of HRQOL among patients
undergoing invasive surgical procedures. Therefore, some
patients achieve durable cancer-free outcomes. It becomes
necessary to safeguard the patients’ HRQOL related to
their bladder cancer and its treatment [3].
In our trial we investigated with validated instruments
the overall quality of life of a very selected population of
patients. In particular, we demonstrated that women un-
dergoing CUS experience a loss of appetite and a wor-
sening of fatigue in daily activities, inducing a worsening
of both the physical and emotional well being.
In our paper some aspects are interesting: the study
was conducted on long term disease free survivors after
RC for clinically localized bladder cancer. This specific
population allows us to avoid biases related to the initial
postoperative worse HRQOL and/or the fear for tumor
recurrence after RC [21]. Moreover, we excluded from
our study both adjuvant-related bother and social/emo-
tional implication of disease progression and obtain
health-related HRQOL results with minimal biases.
A further strength of this paper is the use of more
than one specific validated questionnaire. In the majorityof questionnaires, stratified according to different
BK av VIP av p*
8.7 21.5 ± 6.2 23 ± 2.2
1.3 1.4 (p=n.s.)
1.0 1.0 (p=n.s.)
1.1 1.1 (p=0.054)
1.5 1.6 (p=0.053)
.6 6.8 ± 2.0 6.7 ± 2.0
2.0 1.4 (p=n.s.)
0.5 0.3 (p=n.s.)
.3 6.2 ± 2.1 7.1 ± 1.4
2.0 2.1 (p=n.s.)
2.0 2.0 (p=n.s.)
0.6 0.7 (p=0.008)
1.2 1.3 (p=0.024)
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treatment groups in several clinical trials, such as in our
study: therefore, the use of several questionnaires allow
us to define the minimal variances across different treat-
ment groups.
The quality of life in patients undergoing cystectomy
should take into account many aspects that must be
evaluated in order to have data that comes as close as
possible to the real situation of the patients themselves.
No questionnaire, even if validated, disease specific and
well-built, will take into account all the aspects neces-
sary to have a complete evaluation. For this reason we
decided to use different and validated questionnaires to
evaluate more aspects as possible like: functional, symp-
toms, global health aspects (EORTC QLQ-C30), the effects
of the urostomy (EORTC QLQ -BLM30) and patients
well-being (FACT-BL).
Several Authors, by using a single HRQOL question-
naire, did not find any significant correlation between
HRQOL and the urinary diversion type. Using several
questionnaires it is possible to evaluate different aspects
regarding patients HRQOL. Consequently more differ-
ences, if exist, can be measured. Furthermore the differ-
ences obtained can be evaluated by analyzing several
aspect of patients life that only with multiple items, pro-
vided by multiple questionnaires, would be possible.
Saika et al., by using the EORTC C-30 questionnaire
only, concluded that the type of urinary diversion does
not appear to be associated with a different HRQOL
[22]. In our study, beyond the differences we obtained in
EORTC C-30 regarding “appetite loss” and “fatigue” in
favor of BK-IC/ONB-VIP, the FACT-BL questionnaire
showed a significantly worse HRQOL for CUS compared
with BK-IC/VIP-ONB regarding “physical well being” and
“emotional well being”. This data can be explained by the
fact that patients with CUS showed worse HRQOL out-
comes when compared with BK-IC/VIP-ONB merely for
“appetite loss” and “fatigue” (EORTC QLQ -C30).
The suggested link between the worsening of “appetite
loss” and “fatigue” (EORTC QLQ -C30) and the decli-
ne of “physical well being” and “emotional well being”
(FACT-BL) could be investigated only by using diffe-
rent questionnaires.
Moreover, the multiplicity of aspects investigated al-
lows us to evaluate possible differences between what is
expected based on surgical and anatomical data in lite-
rature and the real quality of life of the patient. For
example during cystectomy the neurovascular bundle
could be damaged [23] causing the worsening of the sex-
ual female quality of life and sexual desire. This aspect
should be affect emotional wellbeing inducing a decline
of the last one. Under these conditions by analyzing both
the sexual aspect (BLM-30) and emotional wellbeing
(FACT-BL) we found that there is no relation betweenthem, in fact we observed a decline physical and emo-
tional wellbeing and no differences in sexual function.
The present study has several limitations that should
be considered when interpreting our results: in par-
ticular, this is a retrospective, cross-sectional, non ran-
domized study in a limited number of patients. It caused
a lack of information about baseline pre-treatment
HRQOL evaluation, even if all data have been collected
and assumed by the case history. However, the possibil-
ity of baseline differences in terms of HRQOL among
the groups cannot be ignored. Some items, not specific
for urological patients, such as mood disturbance or
cognitive status were not included in our evaluation. Be-
cause this was not a randomized clinical trial, certain
biases may have been introduced into analysis that were
not properly controlled for and may have impacted the
outcome, including the policies regarding urological op-
erations in two different urologic centers involved in this
study. In particular, as reported in the “2nd Internatio-
nal Consultation on Bladder Cancer recommendations
on the reconstructive options after radical cystectomy”,
there are no evidences to recommend one form of diver-
sion over another one, in females [24]. Consequently,
the two referral centers that performed RC did not base
the choice for urinary diversion on standard criteria, but
have tailored the UD case-by-case. Therefore, we can
suppose that the loss of appetite and the fatigue as well
as the physical and emotional well-being scores in the
CUS group may depend not only on urinary diversion
but also on patients’ characteristics.
Finally, as suggested by Studer, there is a lack of spe-
cific items regarding the management of the stoma [4].
We need further larger, prospective longitudinal and
randomized studies, in order to confirm these findings
among the urinary diversion groups.Conclusions
In conclusion, based on data from a cross-sectional, non
randomized study in a limited number of cases, females
treated with cutaneous ureterostomy seem to be affected
by a worse HRQOL when compared with those treated
with Bricker or Paduan Ileal Neobladder, for the deteri-
oration of both the physical and emotional perception of
their body image.
Moreover, there is no an exclusive questionnaire that
should be used as gold standard to measure HRQOL in
female after cystectomy: therefore, several validated
questionnaires, investigating different items, scales and
scores, have to be used to measure all the aspects of
quality of life after RC in female, in future studies.
Further randomized prospective studies, based on the
data of our pilot study, are needed to address this im-
portant outcome.
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Additional file 1: Figure S1. Box plot showing differences in physical
well being average score across urinary diversions. (1CUS, 2BK-IC,
3ONB-VIP).
Additional file 2: Figure S2. Box plot showing differences in emotional
well being average score across urinary diversions. (1CUS, 2BK-IC,
3ONB-VIP).
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